Michael Underwood

Proximagen Group Plc engages in the business of discovery and development of therapeutic treatments. The company was founded by Jenner Peter on November 2003 and is headquartered in Cambridge, the United Kingdom.

Part of Istesso Ltd., Modern Biosciences Ltd. is a British pharmaceutical company that manufactures pharmaceutical products. The company is based in London, UK. The company was founded by Samuel Cameron Williams, Alexander James Stevenson. Samuel Cameron Williams has been the CEO since incorporation.

Powderject Pharmaceuticals Plc develops pharmaceutical products. It offers researching, developing, manufacturing and marketing for existing and next generation vaccines. The company was founded in 1993 and is located in Oxford, UK

BenevolentAI Cambridge Ltd. develops novel small molecule therapeutics, in particular in the areas of CNS, pain and inflammation. It specializes in drug development, project management and translational medicine. The company was founded on November 26, 2003 and is headquartered in London, the United Kingdom.

Lifearc provides research services. It specializes in intellectual property management, drug discovery, medical diagnostics and antibody engineering. The firm services include complete technology transfer service for scientists in MRC units and institutes, Awards to Inventors, Collaborative drug discovery and antibody engineering, Funding early stage research with commercial/translational potential and protecting new ideas. The company is headquartered in London, the United Kingdom.

The Drug Information Association is a non-profit multidisciplinary association that operates to promote health and well-being. The non-profit company is based in Horsham, PA. Marwan Fathallah has been the CEO of the company since 2023.

Altimmune UK Ltd. engages in the discovery and development of prophylactic and therapeutic vaccines against mutating viruses and cancer. It provides T-cell vaccines to protect patients against infectious diseases (most notably mutating viruses) and to treat cancers; and Flunisyn, a DepoVaccine to protect against influenza. The company was founded by Bertrand Georges in 2003 and is headquartered in London, the United Kingdom.

DC Biosciences Ltd. provides bioreagents and life science services. The firm’s products include cell extracts, fresh primary mammalian cells, recombinant proteins, steroid beads, fluorescent cell markers, and SILAC reagents. Its services include custom antibody service, custom antibody service, DNA cloning services, gene synthesis service, and protein expression, gene to stable cell line, mass spectrometry, quantitative proteomics, and peptide synthesis. The company was founded by Angus Lamond and Paul Ajuh in June 2006 and is headquartered in Dundee, the United Kingdom.

Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom.

Servier Laboratories Ltd. develops and manufactures pharmaceuticals. Its product portfolio includes Lonsurf, Oncaspar, Pixuvri, Valdoxan, and Natrilix. The company was founded in 1964 and is headquartered in Stoke Poges, the United Kingdom.

University of Birmingham Enterprise Ltd (University of Birmingham Enterprise) is a venture capital subsidiary of University of Birmingham founded in 2008. The firm is headquartered in Birmingham, United Kingdom.

The Institute of Directors (United Kingdom) is a community of passionate UK business leaders. The non-profit company is based in Birmingham, UK, and has subsidiaries in the United Kingdom. The British company provides professional training opportunities and access to essential help and resources for its members. The CEO of the company is Stephen Martin.

Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom.

Adiga Life Sciences, Inc. operates as a healthcare company that conducts medical researches. It develops technologies to control immune function in allergic and auto immune diseases. The company was founded on November 25, 2008 and is headquartered in Hamilton, Canada.

Pleco Therapeutics BV is a Dutch clinical stage specialty pharmaceutical company that aims to improve the effectiveness of existing chemotherapy through its novel plecoid™ therapies. The company is based in Nijmegen, Netherlands. These therapies have the potential to positively change the balance of protein expression within the cancer microenvironment, removing the burden of toxic metals within the cell. The CEO of the company is Ivo Timmermans.